ARD-101

Aardvark Therapeutics (AARD) is testing ARD-101 (denatonium acetate), an oral bitter taste receptor agonist, in a Phase 3 trial for hyperphagia - the relentless, pathological hunger - in Prader-Willi syndrome (PWS). The HERO trial (NCT06828861) was voluntarily paused on February 27, 2026 after reversible cardiac signals emerged in a healthy volunteer study, sending Aardvark's stock down roughly 70% [1]. This is a small company (IPO'd February 2025, ~$94M raised) [2] now fighting to save its lead program in a rare disease space where Soleno Therapeutics already has an approved drug, VYKAT XR, generating ~$190M in its first nine months on market [3].

ARD-101 is a novel compound that has never been approved for any indication. The Phase 3 HERO trial began dosing patients in December 2025 across the US and Australia but was paused in late February 2026 pending a broad review of the cardiac findings with the FDA and external experts [1]. Aardvark expects to provide updated guidance in Q2 2026, though the nature of the cardiac signal - QTc prolongation, arrhythmia, or something else - has not been publicly disclosed, making the timeline for resumption genuinely unknowable. ARD-101 holds Orphan Drug Designation (June 2023) and Rare Pediatric Disease Designation (August 2023) from the FDA [4]. The RPDD is commercially significant: if ARD-101 ever reaches approval, Aardvark receives a Priority Review Voucher worth $100M+ on the secondary market. That voucher represents meaningful option value for a company with a current market cap around $111M. There is also an open-label extension trial (NCT07197034), also paused [5]. Before the pause, Aardvark had guided to topline HERO data in Q3 2026. That timeline is now off the table.

Denatonium is the most bitter compound known to chemistry - it's the stuff added to antifreeze and nail polish remover so you spit it out. ARD-101 repurposes this extreme bitterness as a drug. The human gut is lined with bitter taste receptors called TAS2Rs, the same receptor family found on your tongue. These receptors evolved as poison detectors, and when activated in the intestine, they trigger the release of a cocktail of satiety hormones: GLP-1 (the same target behind Ozempic and Wegovy), CCK (cholecystokinin, a hormone that signals fullness from the upper gut), and PYY (peptide YY, another 'stop eating' signal) [6]. ARD-101 is formulated to stay in the gut - over 99% of the drug remains in the intestinal lumen at therapeutic doses, with minimal absorption into the bloodstream [7]. The idea is elegant: rather than injecting synthetic GLP-1 the way semaglutide does, you trick the gut's own cells into releasing the real thing locally. The open question for PWS is whether this peripheral satiety signal is strong enough to override a fundamentally broken central hunger circuit. PWS patients have a genetic deletion on chromosome 15 that cripples the hypothalamus - the brain's appetite thermostat is stuck on 'starving' regardless of what the gut says [8]. Peripheral approaches like ARD-101 are mechanistically differentiated from drugs that act directly on the brain, but that differentiation cuts both ways: the broken wiring is in the brain, not the gut.

The HERO trial (NCT06828861) is a randomized, double-blind, placebo-controlled Phase 3 study targeting 90 patients aged 7 and older with genetically confirmed PWS [1]. The primary endpoint is change from baseline in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score at 12 weeks - a caregiver-reported instrument that measures food-seeking behaviors, drive to eat, and severity of hyperphagia. Secondary endpoints include the Caregiver Global Impression of Severity and Clinical Global Impression of Severity. Trial sites span the US, Australia, Canada, the UK, and South Korea. The open-label extension (NCT07197034) offers up to 12 months of continued ARD-101 treatment [5]. Before reaching Phase 3, Aardvark ran three Phase 2 trials. The most relevant - an open-label 28-day study in PWS patients (NCT05153434, n=12 completers) - showed 11 of 12 patients with reduced hyperphagia scores, averaging a 7-point HQ-CT reduction, with four patients showing near-complete resolution of hunger symptoms [9]. The controlled obesity trial (NCT05121441, n=20) showed a 2.51-fold greater hunger reduction versus placebo (p=0.015) [9]. These are encouraging signals but carry significant caveats: the PWS study was open-label with no placebo arm, ran for only 28 days, and 7 of 19 enrolled patients did not complete. Behavioral endpoints in open-label rare disease studies routinely outperform controlled settings.

The model gives this drug a 15% chance of eventually being approved. That estimate starts from the historical approval rate for Phase 3 drugs in this area-about 69%-then adjusts based on ten facts about the trial and its sponsor. The number is pulled down mainly by heavier-than-usual blinding, a thin or weak sponsor approval record, weaker earlier-phase results, and smaller-than-typical enrollment. The remaining factors fall close to average for this stage, so they leave the estimate roughly where the base rate started.

ARD-101 is worth monitoring but not worth acting on until Aardvark discloses the specific cardiac finding and the FDA's response. The Q2 2026 guidance is the single data point that determines whether this program lives or dies. If the cardiac signal turns out to be a dose-dependent QTc effect manageable with a lower dose or monitoring protocol, the program resumes and the stock is likely significantly undervalued at current levels. If it's something more structural - an arrhythmia signal, cardiomyopathy, or anything requiring a black box warning in a pediatric population - the program is effectively dead. The mechanism is genuinely interesting. Gut-restricted bitter taste receptor agonism is a novel approach that sidesteps the nausea and injection burden of GLP-1 agonists. The RPDD voucher provides a floor of option value. But Aardvark is a single-asset clinical-stage company trading at roughly its cash value, which tells you the market is pricing near-zero for the pipeline. Check back when Aardvark provides Q2 2026 cardiac data guidance. Until then, this is a binary event story with no edge.